Yes. Some people with PCOS ovulate regularly or occasionally and conceive without fertility treatment. Others may need help with ovulation or additional fertility care. The likelihood depends on individual reproductive and health factors.

No. PCOS can make conception more difficult when ovulation is irregular or absent, but it does not mean that pregnancy is impossible. Many people with PCOS conceive naturally or with assistance.

PCOS can alter hormonal signalling and follicular development. This may result in infrequent ovulation or anovulation, reducing the number of opportunities for conception.

Regular periods do not automatically exclude PCOS. Diagnosis depends on the overall clinical criteria, including androgen-related features and ovarian morphology where relevant, as well as exclusion of other causes.

Not necessarily. Polycystic ovarian morphology can occur without the syndrome. A clinician considers symptoms, hormone findings, ovulatory function and diagnostic criteria before making a diagnosis.

There is currently no single cure for PCOS. Symptoms and associated health risks can often be managed with individualized lifestyle support, medication and fertility treatment when needed.

For some people, weight management may improve metabolic health and reproductive outcomes. Benefits and needs vary, and PCOS also occurs in people who are not overweight. Care should be individualized and free from weight stigma.

No one specific diet has been established as superior for everyone with PCOS. A sustainable, balanced eating pattern tailored to personal needs and preferences is generally encouraged.

Physical activity can support general and metabolic health and may improve well-being. The type and amount should be realistic and appropriate to the individual; exercise alone does not guarantee ovulation or pregnancy.

Assessment may include menstrual and ovulation history, selected hormone tests, metabolic evaluation, pelvic ultrasound, semen analysis and tubal testing when indicated. The clinician selects tests based on the history and treatment plan.

No. AMH is not a stand-alone diagnostic test. In adults, the international guideline allows it as an alternative to ultrasound for assessing polycystic ovarian morphology in certain diagnostic pathways, but it must be interpreted within the full clinical criteria.

The 2023 international evidence-based guideline recommends letrozole as first-line pharmacological ovulation induction for anovulatory infertility due to PCOS when no other infertility factors are present. A clinician must determine whether it is appropriate and permitted locally.

No medicine is suitable for everyone. Letrozole should only be used under medical supervision, and pregnancy must be excluded before treatment. The clinician should discuss possible adverse effects, local regulatory status and monitoring.

Yes. Clomiphene citrate is an ovulation-induction option. It may be used in selected circumstances, and monitoring may be needed because of the increased risk of multiple pregnancy.

Metformin may have a role in selected patients, particularly where metabolic indications are present. It may improve some reproductive outcomes, but more effective ovulation-induction agents are available. It should be prescribed according to individual needs.

Some patients may continue or receive metformin for specific clinical reasons, but it is not routinely recommended in PCOS pregnancy solely to prevent gestational diabetes or late miscarriage. Discuss the indication and potential benefits and uncertainties with your clinician.

Depending on the circumstances, options may include reassessment, gonadotrophin treatment, selected ovarian surgery or IVF. The next step depends on the response to treatment, other infertility factors and personal preferences.

No. IVF is not automatically required. Many patients may conceive naturally or with ovulation induction. IVF may be considered when other treatments have failed or when there is another indication.

Yes. PCOS is associated with increased OHSS risk during ovarian stimulation. The fertility team should discuss this before treatment and offer appropriate strategies to reduce risk.

Yes. Frozen embryo transfer may be part of an IVF plan when suitable embryos are available. The timing and preparation method depend on the clinical situation and the clinic’s protocol.

Single embryo transfer is generally preferred when appropriate because it can minimize multiple pregnancy. The transfer plan should be individualized, with discussion of the benefits and limitations.

PCOS is associated with certain adverse reproductive and pregnancy outcomes in some studies, but individual risk varies and is influenced by several factors. A clinician can discuss personal risk and preconception optimization.

PCOS is associated with increased risk of gestational diabetes. Preconception metabolic assessment and appropriate antenatal screening should be discussed with the healthcare team.

PCOS is associated with an increased risk of hypertensive disorders of pregnancy. Blood pressure assessment and appropriate antenatal monitoring are important components of care.

Folate supplementation is part of routine preconception care. The appropriate dose can depend on individual risk factors, medications and local guidance, so ask your clinician what dose is suitable for you.

Often, yes. Fertility assessment commonly considers both partners. Semen analysis may identify sperm-related factors that would change the investigation or treatment plan.

Yes. PCOS can occur across a range of body sizes. A person’s weight alone neither confirms nor excludes the diagnosis.

Irregular or infrequent periods can suggest irregular ovulation or anovulation, but they do not establish the cause by themselves. A clinician can assess ovulatory function and consider other explanations.

Consider seeking advice when planning pregnancy, when periods are irregular or absent, or when conception has not occurred after trying. Earlier review may be appropriate depending on age, history and other risk factors.

Ask whether you are ovulating, whether other infertility factors need assessment, which treatment is recommended and why, what monitoring is required, what the risks are, and what the next steps would be if treatment is unsuccessful.